-
2 months ago | 
mondaq.com | Sabrina Bellantoni |Matthew Johnson
Recently, a Director Review was granted where Director Vidalvacated the Patent Trial and Appeals Board's ("PTAB")Final Written Decision and remanded back to the PTAB for furtherconsideration of enablement. Duration Media LLC v. RichMedia Club LLC, IPR2023-00953, Paper 78 (December 12,2024). In May 2023, Duration Media LLP ("Petitioner") filed aPetition requesting an inter partes review("IPR") of U.S. Patent No. 11,443,329 ("the '329patent").
-
2 months ago | 
jdsupra.com | Sabrina Bellantoni |Matthew Johnson
Recently, a Director Review was granted where Director Vidal vacated the Patent Trial and Appeals Board’s (“PTAB”) Final Written Decision and remanded back to the PTAB for further consideration of enablement. Duration Media LLC v. Rich Media Club LLC, IPR2023-00953, Paper 78 (December 12, 2024). In May 2023, Duration Media LLP (“Petitioner”) filed a Petition requesting an inter partes review (“IPR”) of U.S. Patent No. 11,443,329 (“the ’329 patent”).
-
2 months ago | 
lexology.com | Sabrina Bellantoni |Matthew Johnson
Recently, a Director Review was granted where Director Vidal vacated the Patent Trial and Appeals Board’s (“PTAB”) Final Written Decision and remanded back to the PTAB for further consideration of enablement. Duration Media LLC v. Rich Media Club LLC, IPR2023-00953, Paper 78 (December 12, 2024). In May 2023, Duration Media LLP (“Petitioner”) filed a Petition requesting an inter partes review (“IPR”) of U.S. Patent No. 11,443,329 (“the ’329 patent”).
-
Nov 1, 2024 | 
mondaq.com | Sabrina Bellantoni |Matthew Johnson
Recently, the Patent Trial and Appeals Board ("PTAB")
released a final written decision finding no challenged claims were
unpatentable in Duration Media LLC v. Rich Media Club LLC,
IPR2023-00953, Paper 74 (August 19, 2024). Of importance, the
petitioner unsuccessfully argued that an asserted prior art patent
was not prior art under pre-AIA 102(b), despite the fact that its
pre-grant publication would have been 102(b) art.
-
Oct 30, 2024 | 
jdsupra.com | Sabrina Bellantoni |Matthew Johnson
Recently, the Patent Trial and Appeals Board (“PTAB”) released a final written decision finding no challenged claims were unpatentable in Duration Media LLC v. Rich Media Club LLC, IPR2023-00953, Paper 74 (August 19, 2024). Of importance, the petitioner unsuccessfully argued that an asserted prior art patent was not prior art under pre-AIA 102(b), despite the fact that its pre-grant publication would have been 102(b) art.
-
Jul 2, 2024 | 
mondaq.com | Matthew Johnson |Sabrina Bellantoni
Recently, District Court Judge Thomas S. Zilly in the Western District of Washington granted Ironburg
Inventions Ltd.'s ("Ironburg") motion for inter
partes review ("IPR") estoppelpursuant to 35
U.S.C. § 315(e)(2), which precludes Valve Corporation
("Valve") from arguing non-petitioned grounds of
invalidity of asserted patent claims in U.S. Patent No. 8,641,525
B2 in Ironburg Inventions Ltd. v. Valve Corporation, No.
2:17-CV-01182. See D.I. 544; 545.
-
Jun 28, 2024 | 
jdsupra.com | Sabrina Bellantoni |Matthew Johnson
Recently, District Court Judge Thomas S. Zilly in the Western District of Washington granted Ironburg Inventions Ltd.’s (“Ironburg”) motion for inter partes review (“IPR”) estoppelpursuant to 35 U.S.C. § 315(e)(2), which precludes Valve Corporation (“Valve”) from arguing non-petitioned grounds of invalidity of asserted patent claims in U.S. Patent No. 8,641,525 B2 in Ironburg Inventions Ltd. v. Valve Corporation, No. 2:17-CV-01182. See D.I. 544; 545.
-
Feb 29, 2024 | 
mondaq.com | Sabrina Bellantoni |Matthew Johnson
Recently, the Patent Trial and Appeals Board ("PTAB")
granted a request for rehearing of a decision that
denied an institution of inter partes review and then instituted a
trial on all the challenged claims on all the grounds raised by the
Petitioner regarding a patent for a cladribine regimen for treating
multiple sclerosis. TWi Pharmaceuticals, Inc. v. Merck
Serono SA, IPR2023-00049, Paper 15 (December 20, 2023).
-
Feb 21, 2024 | 
jdsupra.com | Sabrina Bellantoni |Matthew Johnson
Recently, the Patent Trial and Appeals Board (“PTAB”) granted a request for rehearing of a decision that denied an institution of inter partes review and then instituted a trial on all the challenged claims on all the grounds raised by the Petitioner regarding a patent for a cladribine regimen for treating multiple sclerosis. TWi Pharmaceuticals, Inc. v. Merck Serono SA, IPR2023-00049, Paper 15 (December 20, 2023).
-
Feb 21, 2024 | 
lexology.com | Matthew Johnson |Sabrina Bellantoni
Recently, the Patent Trial and Appeals Board (“PTAB”) granted a request for rehearing of a decision that denied an institution of inter partes review and then instituted a trial on all the challenged claims on all the grounds raised by the Petitioner regarding a patent for a cladribine regimen for treating multiple sclerosis. TWi Pharmaceuticals, Inc. v. Merck Serono SA, IPR2023-00049, Paper 15 (December 20, 2023).
